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Plants are attractive alternative expression hosts for the production of recombinant pro-
teins. Many therapeutic proteins are glycosylated with N - and O-glycosylation being the
most prevalent forms of protein glycosylation.While N -glycans have already been modiﬁed
in plants toward the formation of homogenous mammalian-type glycoforms with equal or
improved biological function compared to mammalian-cell culture produced glycoproteins
little attention has been paid to the modiﬁcation of O-linked glycans. Recently, the ﬁrst
step of mammalian O-glycan biosynthesis has been accomplished in plants. However,
as outlined in this short review there are important issues that have to be addressed in
the future. These include: (i) elimination of potentially immunogenic or allergenic carbo-
hydrate epitopes containing arabinosides or arabinogalactans, (ii) a detailed investigation
of the interplay between engineered N - and O-glycosylation pathways to avoid competi-
tion for common metabolites like UDP-GlcNAc, and (iii) a deeper understanding of signals
and mechanisms for distribution of glycan processing enzymes, which is a prerequisite for
complete and homogenous glycosylation of recombinant proteins.
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INTRODUCTION
Recombinant pharmaceuticals are the fastest growing class of
novel medicine with monoclonal antibodies, hormones like ery-
thropoietin (EPO) and growth factors as the major drivers
(Aggarwal, 2010). The majority of the protein-based therapeu-
tics are glycosylated (Durocher and Butler, 2009) and the impact
of different glycoforms on the function of recombinant pro-
teins is well documented (Jefferis, 2009). Despite these facts,
current mammalian cell culture-based expression systems can-
not produce customized glycoforms on recombinant proteins.
One reason for this inability lies in the complex mammalian
glycome that consists of hundreds of glycosylation enzymes
(Cummings, 2009) and produces an unwanted background gly-
cosylation in expression hosts. Consequently, there is a growing
demand for production systems that allow the control of gly-
cosylation and generate deﬁned homogenous glycans (Rich and
Withers, 2009). Plants are an attractive alternative because they
are cost-effective, highly scalable, free from human pathogens,
and, importantly, can carry out post-translational modiﬁcations
like glycosylation similar to mammals (Ma et al., 2003; Gomord
et al., 2010; Nagels et al., 2012). N- and O-glycans are the two
major carbohydrates on recombinant protein therapeutics. Both
glycosylation types differ in their linkage to the protein back-
bone, their biosynthesis and sugar composition. Engineering
of the N-glycosylation pathway of various plant species led to
remarkable success resulting not only in the removal of immuno-
genic sugar moieties like β1,2-linked xylose and core α1,3-linked
fucose (Koprivova et al., 2004; Strasser et al., 2004, 2008; Cox et al.,
2006; Shin et al., 2011) but also in the complete reconstruction
Abbreviations: EPO, erythropoietin; GalNAc-transferase, UDP-GalNAc:polypep-
tide N-acetylgalactosaminyltransferase; Hyp, hydroxyproline; P4H, prolyl 4-
hydroxylase.
of mammalian glycosylation pathways in plants (Palacpac et al.,
1999; Bakker et al., 2001; Rouwendal et al., 2009; Strasser et al.,
2009; Castilho et al., 2010, 2011; Nagels et al., 2011). In contrast
to that, comparatively little attempts have so far been made to
modify the O-glycosylation machinery of plants. Here, I give a
short overview of recent developments toward the production of
humanized O-glycan structures and summarize challenges for the
future.
MUCIN-TYPE O-GLYCAN BIOSYNTHESIS
O-glycosylation is a common post-translational modiﬁcation of
serine (Ser)/threonine (Thr) residues of secreted and membrane-
bound mammalian proteins. O-glycosylation is fundamentally
different from N-glycosylation as a typical consensus amino acid
sequence has not been clearly identiﬁed yet (Bennett et al., 2012)
and O-glycan biosynthesis occurs in a stepwise fashion involv-
ing the sequential transfer of single sugar residues by distinct
glycosyltransferases. The initiation of mucin-type O-glycan for-
mation, which is the most common O-linked glycan in humans,
encompasses the transfer of an N-acetylgalactosamine (GalNAc)
residue from the nucleotide sugar UDP-GalNAc to hydroxyl side
chains of Ser/Thr. This speciﬁc reaction is catalyzed by a family of
more than20different polypeptideGalNAc-transferases (Figure 1;
Ju et al., 2011; Bennett et al., 2012). Initiation of mucin-type
O-glycosylation in the Golgi suggests that the O-linked struc-
tures are generated entirely post-translationally, after folding and
subunit assembly has been completed in the endoplasmic retic-
ulum. Due to the possibility of various chain elongation and
branching steps there is considerably heterogeneity of mucin-type
O-glycans. Typically these carbohydrates can be further elon-
gated by incorporation of galactose, fucose, N-acetylglucosamine
(GlcNAc) and sialic acid residues in different linkages (Tarp and
Clausen, 2008). Single O-linked glycans are for example found
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FIGURE 1 | O-glycosylation engineering steps required to produce the
disialylated core 1 structure which is, for example, the major O-glycan
on Ser-126 of human EPO (Tsuda et al., 1990). In addition to providing
CMP-NeuAc in the Golgi and initiation of O-glycosylation by transfer of a
GalNAc residue the biosynthesis requires the expression of a mammalian
core 1 β1,3-galactosyltransferase together with its speciﬁc chaperone Cosmc
as well as α2,3- and α2,6-sialyltransferases (Gill et al., 2011; Ju et al., 2011).
These steps are depicted in blue and have not been engineered into plants so
far. The generation of O-GalNAc residues has been shown (Daskalova et al.,
2010; Yang et al., 2012) and the successful expression of the enzymes
(GNE, UDP-N -acetylglucosamine 2-epimerase/N -acetylmannosamine
kinase; NANS, N -acetylneuraminic acid phosphate synthase; CMAS,
CMP-N -acetylneuraminic acid synthetase; NANP, N -acetylneuraminate-
9-phosphate phosphatase, this dephosphorylation step is catalyzed by an
endogenous plant enzyme) for CMP-sialic acid synthesis has been
demonstrated in A. thaliana and N. benthamiana (Castilho et al., 2008, 2010).
In total, the efﬁcient generation of disialylated core 1 structures requires the
expression of at least nine non-plant proteins. According to a recent
publication the ectopic expression of a UDP-GalNAc transporter is not
essential for efﬁcient O-glycosylation initiation in N. benthamiana (Yang et al.,
2012). The requirement of the speciﬁc chaperone Cosmc for core 1
β1,3-galactosyltransferase folding and activity needs to be tested in plants.
on EPO or on interleukin-2, while other human proteins like
mucin-1 (MUC1) or immunoglobulin A (IgA) contain clusters of
O-glycans. Since speciﬁc O-glycans are more abundant on tumors
it has been proposed that peptides containing deﬁned O-glycan
structures can be used as anti-cancer vaccines to elicit an immune
reaction against epitopes present on cancer cells (Springer, 1984;
Ju et al., 2011).
Plants lack the machinery to produce mammalian-type
O-glycosylation (Daskalova et al., 2010; Yang et al., 2012) and
recombinant EPO produced in Nicotiana benthamiana does not
contain any O-linked GalNAc residues (Castilho et al., 2011). To
initiate mucin-type O-glycan formation the corresponding mam-
malian GalNAc-transferase that transfers a single GalNAc residue
to Ser/Thr residues has to be expressed in plants. Apart from
the GalNAc-transferase and the acceptor substrate O-GalNAc
formation depends on the presence of the nucleotide sugar in
the same subcellular compartment. The glycoengineering of the
O-glycosylation initiation step has been reported recently by
two groups. Daskalova et al. (2010) could show by lectin blot-
ting that the transfer of single GalNAc residues to a transiently
expressed O-glycosylation substrate containing human MUC1
tandem repeats requires the expression of three non-plant pro-
teins in N. benthamiana. To generate sufﬁcient amounts of the
UDP-GalNAc donor substrate and transport it into the Golgi
apparatus, a microbial UDP-GlcNAc 4-epimerase and a UDP-
GlcNAc/UDP-GalNAc transporter from nematodes were stably
expressed together with human GalNAc-transferase 2 (Figure 1).
A similar approach was used by Yang et al. (2012) to engi-
neer O-GalNAc residues into three different reporter proteins
transiently expressed in N. benthamiana. Structural analysis by
Frontiers in Plant Science | Plant Biotechnology September 2012 | Volume 3 | Article 218 | 2
“fpls-03-00218” — 2012/9/20 — 12:09 — page 3 — #3
Strasser Plant O-glycans
mass spectrometry conﬁrmed the presence of GalNAc residues
in a MUC1 tandem repeat containing peptide (Yang et al., 2012).
Transient expression of two different human GalNAc-transferases
with partly overlapping substrate speciﬁcities resulted in high-
density O-GalNAc formation on multiple sites of the recombinant
MUC1 peptide. Interestingly, O-glycans were also detected with-
out ectopic expression of a UDP-GalNAc transporter indicating
that the expression of two non-plant proteins is sufﬁcient to
initiate mucin-type O-glycosylation in plants. A possible expla-
nation for the discrepancy between the two studies comes from
differences in the described expression levels. Both groups used
transient expression of their O-glycosylation substrates in N. ben-
thamiana, but in the ﬁrst study the expression of the MUC1
reporter construct was driven by the viral-based magnICON vec-
tor system and resulted in higher expression levels (Daskalova
et al., 2010; Yang et al., 2012). It is therefore possible that at
lower expression an endogenous plant transporter could provide
sufﬁcient amounts of UDP-GalNAc while under high produc-
tivity conditions the nucleotide sugar pool in the Golgi is rate
limiting.
Apart from O-GalNAc formation no further elongation or
branching reactions have been reported so far in plants. One
important elongation is the transfer of a galactose residue in
β1,3-linkage to O-GalNAc to generate a core 1 O-glycan structure
(Galβ1-3GalNAc-Ser/Thr; Figure 1). This reaction is catalyzed in
the Golgi by core 1 β1,3-galactosyltransferase. For efﬁcient fold-
ing human core 1 β1,3-galactosyltransferase is dependent on the
assistance of a speciﬁcmolecular chaperone termedCosmc (Ju and
Cummings, 2002). An ortholog of Cosmc is not present in plants
and consequently it is expected that the efﬁcient formation of core
1 O-glycans on plant-produced recombinant proteins requires the
expression of both mammalian proteins. Alternatively, the expres-
sion of an invertebrate core 1 β1,3-galactosyltransferase that is
functional in the absence of a speciﬁc chaperone and has been
successfully used in an O-glycan engineering approach in yeast
(Amano et al., 2008) could be exploited for this speciﬁc elongation
step. The core 1 structure is the major O-glycan present on IgA1
molecules and hypogalactosylated IgA1 variants result in the elic-
itation of autoantibodies against galactose-deﬁcient IgA1 proteins
(Wada et al., 2010). This ﬁnding highlights the need for expres-
sion systems with controlled O-glycan formation on recombinant
proteins to avoid adverse immunologic reactions.
Another widespread modiﬁcation of mammalian O-glycans is
the attachment of sialic acid in different linkages. Typical disialy-
lated structures are found on glycoprotein hormones like EPO and
small amounts are present in the hinge region of the IgA1 heavy
chain (Mattu et al., 1998). The efﬁcient generation of sialylated
O-glycans involves the expression of the machinery for CMP-N-
acetylneuraminic acid (CMP-NeuAc) biosynthesis and transport
of this nucleotide sugar from the cytoplasm to the Golgi lumen
and distinct sialyltransferases catalyzing the transfer of sialic acid
residues from CMP-NeuAc to O-linked glycans (Figure 1). While
the mammalian sialic acid biosynthesis pathway has been suc-
cessfully constructed in Arabidopsis thaliana and N. benthamiana
(Castilho et al., 2008, 2010), the O-glycan speciﬁc mammalian sia-
lyltransferases required for the generation of sialylated O-glycans
have so far not been expressed in plants.
ENDOGENOUS PLANT O-GLYCOSYLATION
Mammalian O-GalNAc attachment sites are exposed on the
protein surface and frequently contain nearby proline residues.
Expression of recombinant glycoproteins with putative O-gly-
cosylation sites in plants revealed the presence of plant-speciﬁc
glycosylation. In particular, plants convert the proline residues
to hydroxyproline and attach arabinose residues to recombinant
proteins (Karnoup et al., 2005; Pinkhasov et al., 2011). These
non-human glycans can seriously hamper the broad use of
plant-made therapeutics since single arabinosyl residues linked
to hydroxyprolines can constitute an IgE binding epitope and
thus could play a role in allergic reactions (Leonard et al., 2005).
It is currently unclear whether the plant-speciﬁc glycosylation
of hydroxyprolines and mammalian glycosyltransferases com-
pete for adjacent acceptor sites (Daskalova et al., 2010; Pinkhasov
et al., 2011; Yang et al., 2012). Hydroxyproline residues have
been found on MUC1 peptides expressed in N. benthamiana
in the presence and absence of the O-glycosylation machin-
ery necessary for the transfer of GalNAc residues (Yang et al.,
2012). The effect of mammalian-type O-glycosylation on arabi-
nosylation is unclear since no arabinose residues were detected
on the expressed recombinant protein. Moreover, the prolyl 4-
hydroxylases (P4Hs) that are responsible for the conversion of
proline to hydroxyproline in tobacco and related species are not
well described (Yuasa et al., 2005). However, several members
of the A. thaliana P4H family have been characterized recently
(Velasquez et al., 2011), which makes it now practicable to screen
for P4H candidates that hydroxylate speciﬁc proline residues on
recombinant glycoproteins and eliminate them from expression
hosts similar to the successful removal of immunogenic sugar
residues from N-glycans (Strasser et al., 2004, 2008). Such a strat-
egy very likely requires the elimination of several P4Hs with
overlapping substrate speciﬁcities and due to possible effects
on cell wall assembly (Velasquez et al., 2011) it might be nec-
essary to perform tissue-speciﬁc knockouts or knockdowns to
avoid problems with biomass formation and overall growth of
the plants. Apart from preventing P4Hs expression there have
also been attempts to block the formation of hydroxyproline
residues using inhibitors. The ferrous chelator 2,2′-dipyridyl,
which is a potent inhibitor of P4Hs was recently used in tobacco
seedlings to reduce arabinogalactosylation of endogenous pro-
teins (Moriguchi et al., 2011). Such a chemical inhibition strategy
could be quite useful for transient expression but is less suit-
able for the stable expression of O-glycosylated recombinant
proteins.
N- AND O-GLYCAN ENGINEERING
Many valuable recombinant glycoproteins contain both N- and
O-glycans. For example, IgA1 molecules carry in the hinge region
a number of potential O-glycosylation sites, while other domains
of the heavy chain are subjected toN-glycosylation (Ju et al., 2011).
Human EPO contains three N-linked glycans along with a single
O-linked glycan at Ser-126 and also other human plasma proteins
that might be future candidates for plant-based production sys-
tems display several N- and O-glycans that contribute to their
function. Consequently, we are facing the challenge to simul-
taneously modify both pathways in plants to achieve complete
www.frontiersin.org September 2012 | Volume 3 | Article 218 | 3
“fpls-03-00218” — 2012/9/20 — 12:09 — page 4 — #4
Strasser Plant O-glycans
human-like glycosylation. Engineering of N-glycosylation on
recombinant proteins involves the elimination of β1,2-xylose and
core α1,3-fucose, the incorporation of β1,4-galactose as well as
terminal sialic acid residues and branching of N-glycans.
For both N- and O-glycosylation engineering, UDP-GlcNAc is
the common starting metabolite for the generation of nucleotide
sugars (UDP-GalNAc, CMP-NeuAc) required as donor substrates
for the different glycosyltransferases like GalNAc-transferases and
sialyltransferases (Figure 1). Moreover, UDP-GlcNAc is also
used as nucleotide sugar by endogenous N-acetylglucosami-
nyltransferases andmammalianN-acetylglucosaminyltransferases
that initiate branching of N-glycans when expressed in plants
(Strasser et al., 1999; Castilho et al., 2011; Nagels et al., 2011). In
mammals it is well documented that nucleotide sugar biosyn-
thesis is tightly regulated and subjected to feedback regulation.
So far there is no evidence that the engineered changes in the
ﬂux of nucleotide sugars are deleterious for plants. Castilho
et al. (2008) have shown that stable transformed A. thaliana
plants tolerate the generation of high amounts of CMP-sialic
acid and its precursor without any drastic effect on plant growth
and development. Importantly, neither in A. thaliana nor in
N. benthamiana does the expression of the CMP-sialic acid path-
way proteins result in alterations of GlcNAc levels on complex
N-glycans from recombinant proteins. Consistent with that, no
phenotypic changes have been reported in any plant that has
been subjected to N- or O-glycan engineering (Castilho et al.,
2008, 2010; Daskalova et al., 2010; Nagels et al., 2011; Yang et al.,
2012) indicating that plants can efﬁciently maintain intracellular
pools of different nucleotide sugars for the synthesis of vari-
ous glycoconjugates. Although GalNAc has not been detected
in any plant glycan so far, the presence of the corresponding
nucleotide sugar UDP-GalNAc has been shown in A. thaliana sus-
pension cells and in fenugreek endosperm tissue (Alonso et al.,
2010). In both species the UDP-GlcNAc levels are three to four
times higher than the UDP-GalNAc levels. However, the corre-
sponding concentrations in tissues that are used for expression
of recombinant proteins like N. benthamiana leaves and the
steady-state concentration of UDP-GalNAc or other nucleotide
sugars in the Golgi are completely unknown. In view of the fact
that the recent studies on O-glycan engineering did not analyze
N-glycans of recombinant or endogenous proteins its effect on the
N-glycosylation capacity of plants remains to be shown. Clearly,
further research is needed to better understand the nucleotide
sugar interconversion reactions and mechanisms that control their
biosynthesis and subcellular distribution, which will be neces-
sary to achieve complete and highly homogenous glycosylation
in plant expression systems that are subjected to intense N- and
O-glycoengineering.
GOLGI ORGANIZATION OF GLYCOSYLATION ENZYMES
All secreted recombinant glycoproteins pass through the Golgi
where they acquire their ﬁnal glycosylation by Golgi-resident
enzymes that are distributed in sequential Golgi cisternae. The tar-
geting signals and mechanisms that regulate the organization of
glycosylation enzymes in the early secretory pathway of plants are
still poorly understood (Schoberer and Strasser, 2011). A common
feature of the Golgi-located glycosylation enzymes is their type II
membrane protein topology. For several plant glycosyltransferases
and glycosidases it has been demonstrated that the Golgi-targeting
information is present in their N-terminal cytoplasmic, trans-
membrane, and stem (CTS) region without any contribution
from the large luminal catalytic domain (Essl et al., 1999; Saint-
Jore-Dupas et al., 2006; Schoberer and Strasser, 2011). Studies
on the generation of β1,4-galactosylated N-glycans revealed that
sub-Golgi targeting of the human β1,4-galactosyltransferase is
slightly different between plant and mammalian cells leading to
aberrant glycosylation (Palacpac et al., 1999; Bakker et al., 2001;
Strasser et al., 2009). Similar results were observed for mammalian
N-acetylglucosaminyltransferases (Castilho et al., 2011; Nagels
et al., 2011). Replacement of their N-terminal domains with tar-
geting regions from Golgi-resident plant glycosylation enzymes
resulted in a more homogenous glycosylation pattern on recom-
binant proteins. It is apparent from these results that further
approaches to elongate and branch O-glycans need to address the
precise localization of the glycosylation enzymes within the Golgi.
Given the sequential nature of O-glycan biosynthesis it appears
essential to organize glycosyltransferases into some kind of assem-
bly line along the Golgi apparatus. Such an ordered distribution
of glycosylation enzymes across Golgi stacks has been experimen-
tally shown for endogenous plant enzymes involved in N-glycan
processing (Schoberer et al., 2010). However, known targeting
regions might not be sufﬁcient to fulﬁll this goal as there is, for
example, currently only one plant-derived CTS region for trans-
Golgi localization of glycosyltransferases available (Strasser et al.,
2007; Schoberer and Strasser, 2011). It is therefore fundamental to
increase our understanding of the glycosylation enzyme organiza-
tion and cargo transport within the Golgi. Especially, more efforts
are required to decipher sub-Golgi targeting motifs present in the
CTS region of glycosylation enzymes and identify key molecular
players that control their subcellular localization.
CONCLUSION
Developments in the last 10 years have demonstrated that plants
are well suited for the production of recombinant proteins with
homogenous human-like N-glycosylation. The recent progress
in initiation of mucin-type O-glycan formation indicates that
plants are also amenable to engineering of deﬁned mammalian-
type O-glycosylation. However, as summarized here there are
still limitations associated mainly with endogenous plant-speciﬁc
glycosylation, cross-talk between engineered pathways and our
restricted tools for compartmentalization of Golgi-located gly-
can processing enzymes that have to be overcome in the future.
With the rapid progress in this ﬁeld, the combination of N- and
O-glycan modiﬁcation steps is only a matter of time. Furthermore,
current efforts in characterization of hydroxyproline formation
and Golgi-targeting sequences will help to optimize the current
engineering approaches and ultimately will result in the genera-
tion of efﬁcient plant-based production platforms for glycoprotein
therapeutics.
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